WHWKNasdaqPharmaceutical PreparationsFiscal year ends December 31

Whitehawk Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$3.01+0.12 (+4.15%)

Close on Oct 19, 2026

Market cap: $249.49M
P/E (TTM): –
Dividend yield: –

Whitehawk Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31	TTM Q3 2018 2018-09-30	TTM Q2 2018 2018-06-30	TTM Q1 2018 2018-03-31	TTM FY 2017 2017-12-31	TTM Q3 2017 2017-09-30	TTM Q2 2017 2017-06-30	TTM Q1 2017 2017-03-31	TTM FY 2016 2016-12-31	TTM Q3 2016 2016-09-30
Revenue	0	0	7.15	14	22	28	26	25	24	24	24	23	22	19	15	24	20	16	14	14	14	29	14	–	–	–	–	–	–	–	20	–	–	–	–	–	–	–	–	–
Cost of Revenue	0	0	0.76	1.55	2.35	3.13	3.02	3.16	3.05	2.93	2.81	2.10	2.00	1.69	1.34	1.11	0.52	0.18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gross Profit	0	0	6.39	13	19	25	23	22	21	21	22	21	20	17	14	23	19	16	14	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Research & Development	63	99	91	86	82	46	51	49	51	52	49	46	42	37	33	31	28	23	20	18	14	15	15	9.90	10	9.07	13	16	17	19	18	16	15	14	12	10	11	11	11	–
Selling, General & Admin	23	23	30	35	37	39	37	36	40	44	45	45	44	42	40	39	36	27	19	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	19	14	7.11	5.25	2.12	6.52	8.18	8.79	9.76	12	13	13	13	12	11	10	9.24	8.05	7.49	6.55	5.27	3.96
Operating Expenses	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	112	103	19	20	17	17	19	20	24	29	31	33	31	29	26	24	21	18	18	17	17	–
Total Costs & Expenses	86	123	122	123	124	91	93	91	94	98	96	93	88	84	78	74	142	124	112	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Income	-86	-123	-114	-108	-102	-63	-67	-66	-71	-75	-72	-70	-67	-66	-63	-63	-135	-121	-111	-87	-2.22	11	-2.55	-2.18	-4.48	-20	-24	-29	-12	-13	-11	-8.60	-25	-24	-21	-18	-18	-17	-17	-13
Interest Expense	–	–	0	0	0.04	0.10	0.15	0.21	0.23	0.23	0.23	0.23	0.23	0.23	0.23	0.23	0.33	0.50	0.67	0.84	0.91	–	0.82	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.01	0.01
Interest & Investment Income	6.26	6.77	6.23	5.30	4.35	3.43	3.93	4.75	5.45	6.02	6.40	6.51	5.52	4.05	2.40	0.81	0.19	0.03	0.01	–	–	–	0.04	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	6.23	6.90	94	93	92	91	3.77	4.54	5.22	5.79	6.17	6.27	5.29	3.81	2.17	0.57	0.24	2.48	1.13	0.79	0.34	-1.98	-0.93	0.20	0.75	1.02	1.17	1.31	1.33	1.08	0.78	0.49	0.26	0.28	-0.01	-0.28	-0.53	-0.60	-0.35	–
Merger & Restructuring Charges	0	0	0	0	2.64	2.64	2.64	2.64	0	–	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.86	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-0.18	-0.18	87	87	87	87	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	–	–	–	–	–	–	–	–	–	–	-66	–	–	–	-61	-63	-135	-118	-110	-86	-1.88	–	-3.48	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	0	0	0	0	0	0	0	0	0	0	0	-0.01	-0.01	0	0	0.01	0.01	0.00	0.00	–	–	–	0.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-80	-116	-21	-16	-10	28	-64	-62	-65	-69	-66	-63	-62	-62	-61	-63	-135	-118	-110	-86	-1.88	-5.63	-3.48	-16	-18	-18	-23	-27	-11	-11	-10	-8.11	-24	-24	-21	-19	-19	-18	-17	-13
Preferred Dividends	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.65	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-111	–	–	–	–	–	-3.74	-19	-23	-27	-11	-11	-10	-8.11	-24	-24	-22	-21	-22	-22	-21	–
EPS (Basic)(per share)	–	–	–	0.15	-0.05	0.17	-2.36	-2.28	-2.42	-2.55	-2.44	-2.36	-2.44	-2.64	-2.69	–	–	–	–	–	–	–	–	-0.90	-1.50	-7.67	-9.50	-11.17	-4.67	-6.00	-5.17	-7.33	-14.83	-14.67	-17.17	-103.33	-212.00	-313.50	-408.67	–
EPS (Diluted)(per share)	–	–	–	0.14	-0.06	0.16	-2.36	-2.28	-2.42	-2.55	-2.44	-2.36	-2.44	-2.64	-2.69	–	–	–	–	–	–	–	–	-0.90	-1.50	-7.67	-9.50	-11.17	-4.67	-6.00	-5.17	-7.33	-14.83	-14.67	-17.17	-103.33	-212.00	-313.50	-408.67	–
Shares Outstanding (Basic, Weighted)(shares)	73	69	62	51	41	30	27	27	27	27	27	27	25	24	23	–	–	–	–	4.28	2.54	2.52	2.54	2.46	2.44	2.44	2.44	2.44	2.43	2.24	2.04	1.83	1.62	1.62	1.30	0.91	0.52	0.12	0.05	0.05
Shares Outstanding (Diluted, Weighted)(shares)	72	69	62	51	41	30	27	27	27	27	27	27	25	24	23	–	–	–	–	4.28	2.54	2.52	2.54	2.47	2.44	2.44	2.44	2.44	2.44	2.24	2.04	1.83	1.62	1.62	1.30	0.91	0.52	0.12	0.05	0.05
EBITDA	–	–	–	–	–	–	–	–	–	-74	-72	-70	-67	-66	-63	-63	-135	-121	-111	-87	–	–	-2.54	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Provision for Credit Losses	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.17	–	–	–	0.17	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -21.8%

Financial strength

Current ratio: 17.38
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 770.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.36
Dividend yield: –